COMPANY

Georgiamune

HQ: Gaithersburg, MD source · georgiamune.com ↗ · Mid-Atlantic

Keywords: antibody oncology small molecule Melanoma Stage IV GIM122 GIM-531 GIM-407

Location: Gaithersburg, MD · source · Oct 14, 2026

Profile checked Oct 10, 2026

Funding and NIH signals

SEC Form D raise Raised $92.69M (Form D filed Aug 17, 2026). SEC Form D 0000905148-26-003774 (Aug 17, 2026)
Evidence (1 event)
- Aug 17, 2026 · SEC Form D 0000905148-26-003774
  Name of Issuer: Georgiamune, Inc.; CIK: 2148230; Address: Gaithersburg, MD; Submission type: D; Filing date: 2026-08-17; Industry Group: Biotechnology; Date of First Sale: 2026-07-16; Types of Securities Offered: Equity, Other (Series B Preferred Stock); Business combination transaction: false; Total Offering Amount: 131852011; Total Amount Sold: 92692709; Federal exemptions: 06b

Job counts as of Oct 18, 2026. All funding and NIH signals

Sep 2, 2024 Trial start Phase 1: The Purpose of the Study is to Evaluate the Safety, Tolerability and Pharmacokinetics of Single-ascending and Multiple-ascending Doses of GIM-407 source ↗
May 9, 2024 Trial start Phase 1/Phase 2: Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors source ↗
Dec 12, 2023 Trial start Phase 1/Phase 2: Safety and Tolerability Study of GIM-122 in Subjects With Advanced Solid Malignancies source ↗

2026-12 (ESTIMATED) · Phase 1/Phase 2 · Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors · NCT06425926

Estimated primary completion per ClinicalTrials.gov. Dates move.

Record	Title	Phase	Status	Start	Primary completion
NCT06028074	Safety and Tolerability Study of GIM-122 in Subjects With Advanced Solid Malignancies	Phase 1/Phase 2	Recruiting	Dec 12, 2023	2026-09 (estimated)
NCT06425926	Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors	Phase 1/Phase 2	Recruiting	May 9, 2024	2026-12 (estimated)
NCT06536101	The Purpose of the Study is to Evaluate the Safety, Tolerability and Pharmacokinetics of Single-ascending and Multiple-ascending Doses of GIM-407	Phase 1	Completed	Sep 2, 2024	Apr 5, 2025 (actual)